MedTrace Logo

FSRT Combined With TMZ for Large BMs: a PSM Study

NCT03338075 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2017-11-09

No results posted yet for this study

Summary

A propensity- matched study was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.

Conditions

Interventions

RADIATION

fractionated stereotactic radiotherapy

The regular prescription doses were 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Jianping Xiao, Dr · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2017-08-01
Completion
2017-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03338075 on ClinicalTrials.gov